Cytosorbents News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.09.17	CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference (PR Newswire)
05.09.17	CytoSorbents Highlights Important Research Advances in Traumatic Brain Injury, Hemorrhagic Shock, and Severe Hyperkalemia at the Military Health System Research Symposium (PR Newswire)
14.08.17	CytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients (PR Newswire)
07.08.17	CytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017 (PR Newswire)
02.08.17	Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb® (PR Newswire)
02.08.17	Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb® (PR Newswire)
02.08.17	Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb® (PR Newswire)
01.08.17	CytoSorbents to Report Q2 2017 Operating and Financial Results (PR Newswire)
27.07.17	AllianceBernstein Holding L.P. Announces Second Quarter Results (PR Newswire)
17.07.17	CytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR (PR Newswire)
13.07.17	CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma (PR Newswire)
05.07.17	CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank (PR Newswire)
28.06.17	ABI Research Survey Finds More than 50% of Government Respondents Call for Public Technology Management at the Local Level (PR Newswire)
15.06.17	CytoSorbents Announces Director and Management Open Market Stock Purchases (PR Newswire)
06.06.17	CytoSorbents - A Leader in Blood Purification to Treat Deadly Inflammation - Teams with Investor Relations Firm LifeSci Advisors (PR Newswire)
30.05.17	Dr. Eric G. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer (PR Newswire)
24.05.17	CytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference (PR Newswire)
22.05.17	Aferetica and CytoSorbents Extend Exclusive "Life-saving" Partnership through 2021 (PR Newswire)
09.05.17	Concierge Auctions Reveals Its International May/June 2017 Lineup Featuring 17 One-Of-A-Kind Properties (PR Newswire)
08.05.17	CytoSorbents Reports First Quarter 2017 Financial Results (PR Newswire)
07.05.17	TXMD All Set For D-day, IMMU Soars On Strategic Plan, CTSO On Watch (RTTNews)
24.04.17	CytoSorbents Awarded $1M Phase II SBIR Contract by U.S. Department of Defense to Advance Fungal Mycotoxin Blood Purification (PR Newswire)
19.04.17	CytoSorbents 2017 - Propelling the Company to the "Next Level" (PR Newswire)
03.04.17	BioDirection Announces Results from Pre-Clinical Study of Tbit™ System for Detection of Traumatic Brain Injury (PR Newswire)
30.03.17	CytoSorbents Announces Proposed Offering of Common Stock (PR Newswire)
28.03.17	CytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia (PR Newswire)
27.03.17	CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference (PR Newswire)
22.03.17	Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins CytoSorbents Scientific Advisory Board (PR Newswire)
20.03.17	CytoSorb® Treatment of HLH - The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy (PR Newswire)
16.03.17	CytoSorbents Announces CytoSorb® Partnership with Dr. Reddy's Laboratories (PR Newswire)
07.03.17	CytoSorbents Highlights Activities at the 22nd International Conference on Advances in Critical Care Nephrology (PR Newswire)
06.03.17	CytoSorbents to Present at the Maxim Group - Haitong Securities Inaugural Healthcare Investor and Partnering Conference (PR Newswire)
02.03.17	CytoSorbents to Present at 37th Annual Cowen and Company Healthcare Conference (PR Newswire)
24.02.17	CytoSorbents to Report Fiscal 2016 Operating and Financial Results (PR Newswire)
07.02.17	CytoSorbents to Present at the 19th Annual BIO CEO & Investor Conference (PR Newswire)
11.01.17	Fresenius Medical Care und CytoSorbents erweitern ursprüngliche Partnerschaft und fügen neue Co-Marketing-Vereinbarung für CytoSorb®-Märkte weltweit hinzu (PR Newswire)
11.01.17	Fresenius Medical Care and CytoSorbents Expand Original Partnership and Add New Co-Marketing Agreement for Worldwide CytoSorb® Markets (PR Newswire)
11.01.17	Fresenius Medical Care et CytoSorbents élargissent leur partenariat initial et ajoutent un nouvel accord de co-marketing pour les marchés CytoSorb® à l'échelle mondiale (PR Newswire)
09.01.17	Fresenius Medical Care and CytoSorbents Expand Original Partnership and Add New Co-Marketing Agreement for Worldwide CytoSorb® Markets (PR Newswire)
03.01.17	CytoSorbents To Provide Corporate Update at Biotech Showcase 2017 (PR Newswire)
12.12.16	CytoSorbents Receives $318,551 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program (PR Newswire)
07.12.16	CytoSorb® Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany (PR Newswire)
02.12.16	CytoSorbents to Present at the LD Micro Main Event Investor Conference (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Cytosorbents Corp

Aktien Top/Flop

Meistgelesene Nachrichten